KOSDAQBiotech & Pharma270520

Aptn

₩818▼ 1.68%2026-10-02 close

Market Cap

₩32.7B

Turnover

₩900M

Volume

Shares out.

40M

PER

—

PBR

—

EPS

—

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Apton's Fifth Pivot: Betting the Company on GPC-100

Having started as a geothermal energy company before pivoting through lithium, a Parkinson's disease drug program, and virtual assets, Apton has now secured global rights to blood-cancer drug candidate GPC-100 and launched a US Phase 3 trial, even as its legacy revenue softens and losses widen.

1
Since its 2020 KOSDAQ listing, the company has shifted its core identity five times: geothermal energy, lithium, a Parkinson's disease drug, virtual assets, and now GPC-100 biotech.
2
In 2025, revenue was KRW 16.895 billion, the operating loss was KRW 11.157 billion, and the net loss attributable to owners was KRW 23.431 billion — revenue declined while the net loss actually widened.
3
In August 2026, the company announced it had secured global exclusive rights to hematopoietic stem cell mobilizer 'GPC-100 (Burixafor),' which holds FDA orphan drug designation, and disclosed the start of a US Phase 3 trial.
4
Over the trailing four quarters (Q3 2025–Q2 2026), combined revenue was about KRW 15.4 billion, while the combined net loss attributable to owners reached roughly KRW 29.0 billion — a loss burden far exceeding revenue scale.
5
Concerns have also been raised in the market regarding related-party transactions with controlling shareholder Aprogen, including intercompany loans and capital increases.

Business structure

Apton began as a geothermal and hydrothermal HVAC and fuel-cell design-and-construction company that listed on KOSDAQ in 2020 through a SPAC merger, with a track record on large projects including the Lotte World Tower in Jamsil and the Sejong City government complex.

After being acquired by a consortium including Entotech in 2022, it added a lithium business tied to EV battery materials and renamed itself Georit Energy in 2023.

In January 2025, biosimilar company Aprogen became the controlling shareholder, the name changed to APT Neuroscience, and the company acquired Parkinson's disease-related patents developed by a Seoul National University professor to establish a brain-disease drug unit.

In June 2025 it renamed itself Apton again, establishing a virtual-asset treasury division, and in September acquired a 69.1% stake in Golden Futures, operator of crypto exchange Bitcmon, for about KRW 5.1 billion.

In 2026, the company invested a total of KRW 10 billion in biotech firm GPCR, which holds a CAR-T booster platform, to secure controlling ownership and add a new drug pipeline.

That August, Apton paid KRW 6.5 billion to GPCRT to secure global exclusive rights to hematopoietic stem cell mobilizer Burixafor (GPC-100), while committing up to KRW 472 billion in milestone payments to the original developer, GPCR.

Across roughly four years, Apton has thus shifted its core identity five times — geothermal energy, lithium, a brain-disease drug, virtual assets, and now an oncology drug candidate — and while legacy geothermal and fuel-cell revenue still exists, new-business investment now drives the company's direction.

Competitively, GPC-100 is set to enter the market following the same CXCR4-class drug Motixafortide (Aphexda), which has already received FDA approval.

Earnings trend

Quarterly revenue · Operating profit

₩2.8B-₩4B25Q2₩5.2B-₩1B25Q3₩2.3B-₩3.6B25Q4₩4.5B-₩1.8B26Q1₩3.4B-₩1.3B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩17.6B-₩3.1B2022₩20.4B-₩6.5B2023₩18.4B-₩12.8B2024₩16.9B-₩11.2B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩2.8B	-₩4B	−140.7%
2025Q3	₩5.2B	-₩1B	−20.1%
2025Q4	₩2.3B	-₩3.6B	−156.5%
2026Q1	₩4.5B	-₩1.8B	−39.1%
2026Q2	₩3.4B	-₩1.3B	−39.4%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩17.6B	-₩3.1B	-₩3.2B	−17.8%	−7.7%	56.1%
2023	₩20.4B	-₩6.5B	-₩5B	−32.1%	−8.6%	68.7%
2024	₩18.4B	-₩12.8B	-₩19.2B	−69.4%	−23.7%	155.1%
2025	₩16.9B	-₩11.2B	-₩23.4B	−66.0%	−24.6%	68.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23

Earnings analysis

Apton's consolidated revenue rose from KRW 17.563 billion in 2022 to KRW 20.415 billion in 2023, then declined for two consecutive years to KRW 18.378 billion in 2024 and KRW 16.895 billion in 2025.

The operating loss widened each year from KRW 3.133 billion in 2022 to KRW 6.546 billion in 2023 and KRW 12.752 billion in 2024, before narrowing slightly to KRW 11.157 billion in 2025.

The operating margin deteriorated from -17.8% in 2022 to -69.4% in 2024 before standing at -66.0% in 2025, still reflecting a deeply loss-making structure.

By contrast, the net loss attributable to owners moved in the opposite direction, widening from KRW 3.248 billion in 2022 and KRW 5.003 billion in 2023 to KRW 19.167 billion in 2024 and KRW 23.431 billion in 2025.

On a quarterly basis, the net loss reached KRW 20.901 billion in Q2 2025, heavily influencing the full-year figure, followed by KRW 4.269 billion in Q3, KRW 7.634 billion in Q4, KRW 13.216 billion in Q1 2026, and KRW 3.871 billion in Q2 2026 — showing very high quarter-to-quarter volatility.

Over the trailing four quarters (Q3 2025–Q2 2026), combined revenue was about KRW 15.402 billion, the combined operating loss was about KRW 7.772 billion, and the combined net loss attributable to owners was about KRW 28.990 billion, a loss burden far exceeding the revenue base.

Operating cash flow (CFO) swung from an inflow of KRW 1.152 billion in 2022 to outflows of KRW 4.682 billion in 2023, KRW 10.234 billion in 2024, and KRW 40.024 billion in 2025, showing a marked acceleration in cash burn.

Equity grew from KRW 42.362 billion in 2022 to KRW 95.184 billion in 2025, but this reflects continuous external fundraising through rights issues and convertible bonds rather than accumulated profit, while the debt ratio declined from 155.1% in 2024 to 68.2% in 2025.

Industry analysis

In the global blood-cancer treatment market, multiple myeloma drug Darzalex (daratumumab) grew large enough that its 2025 revenue reached $9.744 billion (about KRW 13 trillion).

However, Darzalex has been noted for a side effect in which it binds not only to cancer cells but also to hematopoietic stem cells and white blood cells, hindering their movement.

Against this backdrop, interest has grown in mobilizing agents that move hematopoietic stem cells and immune cells into peripheral blood, and the case of same-class (CXCR4) drug Motixafortide (Aphexda), which won FDA approval in September 2023 based on a single Phase 3 trial of just 122 patients, has become a benchmark for follow-on developers.

GPC-100 differentiates itself on speed: while existing mobilizers take 10-14 hours to take effect, Phase 2 data confirmed it acts within one hour of dosing. The company also views GPC-100 as potentially usable beyond simple mobilization, as a booster platform that could enhance the efficiency of in-vivo CAR-T therapy.

Meanwhile, Apton's legacy geothermal and hydrothermal HVAC and fuel-cell construction business is tied to domestic renewable-energy policy and construction cycles, with analysis pointing to declining core revenue and gross margin turning negative amid rising raw material costs.

The virtual-asset business is being pursued as part of a group-wide diversification strategy amid intense competition in the domestic crypto exchange market.

Outlook

On August 31, 2026, the company formalized the start of a US Phase 3 trial for GPC-100, stating it plans to finalize the protocol with the FDA based on Phase 2 results in the US and move quickly into late-stage development.

The stated goal is early approval via a small, single Phase 3 trial in the style of Motixafortide, with the company targeting approval within two years based on a single trial of roughly 120 patients.

The GPCR investment is being executed in three tranches, with two more third-party capital increase payments scheduled for September 21 and November 20, 2026, meaning further funding commitments are still ahead.

Under the Burixafor licensing agreement, up to KRW 472 billion in milestone payments could be due to original developer GPCR across development and approval stages, implying additional payment obligations depending on how the trial progresses.

In the virtual-asset segment, group-level expansion through Bitcmon and related entities continues, and changes in the domestic regulatory environment for such businesses also warrant attention.

No clear news of major new orders has emerged for the legacy geothermal and fuel-cell business, suggesting that new-business outcomes are likely to be the primary driver of overall results going forward.

Valuation

PER

—

PBR

—

ROE

-31.9%

EPS

—

BPS

—

Dividend per share

₩0

Apton has seen its share count steadily rise in recent years amid repeated business pivots and large-scale rights issues and convertible bond issuances, and given the sizable gap between the annual weighted-average and year-end share counts, this dilution effect should be factored into any reading of per-share metrics.

With losses persisting, the price-to-earnings ratio remains not meaningful for extended periods, making it difficult to apply an earnings-based valuation lens as-is.

On a price-to-book basis, the shares trade at a level below net asset value per share, suggesting the market is not fully crediting the company's reported net asset value. No dividend is being paid, so comparing investment appeal via dividend yield is not meaningful at this stage.

Given that equity growth stems from external fundraising rather than accumulated profit, the qualitative composition of that net asset value warrants closer scrutiny.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23

Bull factors

Securing the GPC-100 Drug Asset with FDA Orphan Designation

In August 2026, Apton secured global exclusive rights to hematopoietic stem cell mobilizer Burixafor (GPC-100), which already holds FDA orphan drug designation.

Because same-class drug Motixafortide won FDA approval in 2023 based on a single Phase 3 trial of just 122 patients, the company argues it could pursue approval with a relatively small patient population.

If executed as planned, this path could shorten development time and reduce costs compared with typical large-scale oncology trials.

Diversified Business Portfolio and New Asset Acquisitions

Beyond its core geothermal business, the company has acquired multiple new-business assets in a short period, spanning a Parkinson's disease drug program, virtual assets, and the GPC-100 oncology candidate. If even some of these succeed, the structure offers multiple potential catalysts simultaneously.

It has also been noted that Apton could leverage parent Aprogen's biosimilar and antibody CDMO experience and infrastructure through joint R&D arrangements.

Improved Headline Financial Structure via Capital Raises

Equity grew from KRW 42.362 billion in 2022 to KRW 95.184 billion in 2025, and the debt ratio fell from 155.1% in 2024 to 68.2% in 2025, expanding the company's headline financial capacity. This could serve as a foundation for further fundraising needed to support new-business investment.

Bear factors

Declining Core Revenue and Accelerating Cash Burn

Consolidated revenue peaked at KRW 20.415 billion in 2023 before declining for two straight years to KRW 18.378 billion in 2024 and KRW 16.895 billion in 2025. Operating cash flow swung from an inflow of KRW 1.152 billion in 2022 to an outflow of KRW 40.024 billion in 2025, a sharply widening deterioration.

The trailing four-quarter net loss attributable to owners reached about KRW 28.990 billion, far exceeding the revenue base, indicating a fast pace of cash depletion without an underlying profit structure.

Identity and Execution Risk from Repeated Business Pivots

Across roughly four years, Apton has changed its name and core business identity five times — geothermal energy, lithium, a brain-disease drug, virtual assets, and now the GPC-100 oncology candidate.

Such repeated pivots over a short span can raise questions about resource focus and execution capability for each individual business. Most of the new ventures remain at an early stage that has not yet generated commercial revenue.

Market Concerns over Related-Party Transactions and Governance

Some media reports have pointed to instances in which Apton lent funds to parent Aprogen on terms below market interest rates and recognized an accounting loss as a result. Such intercompany fund transfers have also drawn commentary suggesting possible tension with self-dealing provisions under corporate law.

The fact that controlling ownership and governance have changed rapidly and repeatedly is also something investors may wish to consider.

Risk factors

Clinical and Regulatory Risk

GPC-100 has only completed Phase 2, and its Phase 3 protocol has not yet been finalized with the FDA; the trial outcome and any approval remain unconfirmed.

Any delay or failure in the trial could significantly undermine expectations tied to the milestone asset value of up to KRW 472 billion cited in the licensing arrangement.

Funding and Dilution Risk

The company has repeatedly raised funds in recent years through rights issues and convertible bonds, and its year-end share count (23,158,914 shares) is materially higher than the annual weighted-average share count (19,662,551 shares).

If additional funding is needed for the GPC-100/GPCR investment or milestone payments, further dilution of existing shareholders could follow.

Affiliate and Governance Risk

Since Aprogen became the controlling shareholder, the company's business purpose and name have changed multiple times in a short span, and controversies have been raised regarding intercompany loans and investments.

Governance-related issues represent a variable that can affect share price and market trust independent of drug-development outcomes.

What to watch next

September 21, 2026
The scheduled date for the second-tranche third-party capital increase payment (about KRW 3 billion) and share acquisition in GPCR, offering a checkpoint on whether the drug-pipeline investment is actually proceeding as planned.
November 20, 2026
The scheduled date for the third-tranche GPCR investment payment (about KRW 4 billion), which will show whether the total KRW 10 billion investment is completed and controlling ownership is confirmed.
Around mid-November 2026, at the Q3 2026 quarterly report filing
The Q3 2026 filing should be checked to see how GPC-100-related R&D expenses are being reflected, along with revenue trends and the pace of cash burn.
After the US Phase 3 protocol for GPC-100 is finalized
Once the final Phase 3 protocol negotiated with the FDA (patient number, design, primary endpoint) is disclosed, the realism of the development timeline should be reassessed.
Whenever a disclosure regarding GPCR milestone payments occurs
Whether the conditions for the first tranche of the up-to-KRW-472-billion milestone are met will provide a basis for assessing the real value of the drug asset.

Overall view

Apton began as a geothermal energy company and has since shifted its core identity five times within a short period, moving through lithium, a Parkinson's disease drug program, virtual assets, and now blood-cancer drug candidate GPC-100.

Confirmed financials show revenue declining for two straight years since 2023, and while the operating loss narrowed slightly after peaking in 2024, the net loss attributable to owners and operating cash flow both deteriorated further.

Even on a trailing four-quarter basis, the net loss remains far larger than revenue, and the growth in equity reflects reliance on external fundraising rather than profit.

Securing global exclusive rights to FDA-orphan-designated GPC-100 and starting a US Phase 3 trial in August 2026 form the core of the company's new growth narrative, but clinical outcomes and any eventual approval remain unconfirmed future events.

At the same time, market concerns persist over the repeated business pivots and intercompany fund transfers, meaning the potential of the drug pipeline and the financial/governance risks warrant equal attention.

Investors will likely need to continue monitoring the upcoming GPCR investment payments, the finalization of the Phase 3 protocol, and quarterly earnings disclosures to gauge whether this fifth pivot translates into tangible results.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.